Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2009 | Original Article

Effective treatment of pancreatic neuroendocrine tumours transfected with the sodium iodide symporter gene by ¹⁸⁶Re-perrhenate in mice

Authors: Christoph G. U. Riese, Stephan Seitz, Meike L. Schipper, Thomas M. Behr

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2009

Abstract

Purpose

ReO ₄ ⁻ has similar kinetics regarding the sodium iodide symporter (NIS) to I⁻ and TcO ₄ ⁻ in NIS-expressing tissue. We investigated the therapeutic potential of ¹⁸⁶ReO ₄ ⁻ in NIS-transfected neuroendocrine tumour tissue.

Methods

For experiments, the stably NIS-transfected pancreatic neuroendocrine cancer cell line Bon1C was used. NIS-mediated internalization and externalization experiments in vitro and a biodistribution study in nude mice bearing Bon1C xenografts were performed. A therapy study was also conducted consecutively in nude mice xenografted with Bon1C in which the mice were injected intravenously with Na¹⁸⁶ReO₄.

Results

In vitro studies showed exponential internalization and efflux kinetics of ¹⁸⁶ReO ₄ ⁻ in the cell line. The biodistribution study showed high uptake of ¹⁸⁶ReO ₄ ⁻ in NIS-expressing tumours. Tumour growth inhibition was significant after injection of ¹⁸⁶ReO₄ in two groups of animals treated with activity levels below the determined maximum tolerable activity as compared to controls.

Conclusion

These results indicate that the use of ¹⁸⁶ReO ₄ ⁻ in the treatment of NIS-expressing neuroendocrine tumours is feasible and support the concept of using NIS as a therapeutic target for ¹⁸⁶ReO ₄ ⁻ .

Oberg K. The ultimate biochemical diagnosis of gastro-enteropancreatic tumours. Digestion 1996;57(Suppl 1):45–7. doi: 10.1159/000201394.PubMed

Stridsberg M. The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours. Ups J Med Sci 1995;100(3):169–99.PubMedCrossRef

Öberg K. Carcinoid tumours: current concepts in diagnosis and treatment. Oncologist 1998;3(5):339–45.PubMed

Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumours: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8(7):685–90. doi:10.1023/A:1008215730767.CrossRefPubMed

Pucci A, Bartoloni G, Tessitore E, Carney JA, Papotti M. Cytokeratin profile and neuroendocrine cells in the glandular component of cardiac myxoma. Virchows Arch 2003;443(5):618–24. doi:10.1007/s00428-003-0882-3.CrossRefPubMed

Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458–60. doi:10.1038/379458a0.CrossRefPubMed

Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339–45. doi:10.1006/bbrc.1996.1358.CrossRefPubMed

Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na+/I- symporter mechanism, stoichiometry and specificity. J Biol Chem 1997;272:27230–8. doi:10.1074/jbc.272.43.27230.CrossRefPubMed

Emamian SA, Shalaby-Rana E, Majd M. The spectrum of heterotopic gastric mucosa in children detected by Tc-99m pertechnetate scintigraphy. Clin Nucl Med 2001;26:529–35. doi:10.1097/00003072-200106000-00010.CrossRefPubMed

10.

Berquist TH, Nolan NG, Stephens DH, Carlson HC. Specificity of 99mTc-per-technetate in scintigraphic diagnosis of Meckels diverticulum: review of 100 cases. J Nucl Med 1976;17:465–9.PubMed

11.

Meine FJ, Woloshin HJ. Radiologic diagnosis of salivary gland tumours. Radiol Clin North Am 1970;8:475–85.PubMed

12.

Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium-188 as an alternative to iodine-131 for treatment of breast tumours expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002;29:13–8. doi:10.1016/S0969-8051(01)00279-7.CrossRefPubMed

13.

Chow SM, Law SC, Mendenhall WM, Au SK, Chan PT, Leung TW, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002;2002(52):784–95. doi:10.1016/S0360-3016(01)02686-4.CrossRef

14.

De la Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083–105.

15.

Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000;6:871–8. doi:10.1038/78630.CrossRefPubMed

16.

Kilbane MT, Ajjan RA, Weetman AP, Dwyer R, McDermott EW, O’Higgins NJ, et al. Tissue iodine content and serum-mediated 125-I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab 2000;85:1245–50. doi:10.1210/jc.85.3.1245.CrossRefPubMed

17.

Cho JY, Xing S, Liu X, Buckwalter TL, Hwa L, Sferra TJ, et al. Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 2000;7:740–9. doi:10.1038/sj.gt.3301170.CrossRefPubMed

18.

Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumours for a targeted radiotherapy. Cancer Res 2000;60:3484–92.PubMed

19.

Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59:661–8.PubMed

20.

Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999;59:2136–41.PubMed

21.

Spitzweg C, O’Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000;60:6526–30.PubMed

22.

Schipper ML, Riese CG, Seitz S, Weber A, Béhé M, Schurrat T, et al. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS) expressing neuroendocrine tumours in vivo. Eur J Nucl Med Mol Imaging. 2007;34(5):638–50.CrossRefPubMed

23.

Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med 2004;45:500–7PubMed

24.

Schipper ML, Weber A, Béhé M, Göke R, Joba W, Schmidt H, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumour cells. Cancer Res 2003;63(6):1333–8.PubMed

25.

Haberkorn U, Beuter P, Kübler W, Eskerski H, Eisenhut M, Kinscherf R, et al. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. J Nucl Med 2004;45(5):827–33.PubMed

26.

Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001;42(2):317–25.PubMed

27.

Min JJ, Chung JK, Lee YJ, Shin JH, Yeo JS, Jeong JM, et al. In vitro and in vivo characteristics of a human colon cancer cell line, SNU-C5N, expressing sodium-iodide symporter. Nucl Med Biol 2002;29(5):537–45. doi:10.1016/S0969-8051(02)00304-9.CrossRefPubMed

28.

Nakamoto Y, Saga T, Misaki T, Kobayashi H, Sato N, Ishimori T, et al. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy. J Nucl Med 2000;41(11):1898–904.PubMed

29.

Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology 1997;138(10):4493–6. doi:10.1210/en.138.10.4493.CrossRefPubMed

30.

Dingli D, Bergert ER, Bajzer Z, O’Connor MK, Russell SJ, Morris JC. Dynamic iodide trapping by tumour cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun 2004;325(1):157–66. doi:10.1016/j.bbrc.2004.09.219.CrossRefPubMed

31.

Jhiang SM, Cho JY, Ryu KY, De Young BR, Smanik PA, McGaughy VR, et al. An immunohistochemical study of Na+/I- symporter in human thyroid tissue and salivary gland tissues. Endocinology 1998;139:4416–9. doi:10.1210/en.139.10.4416.CrossRef

32.

Josefsson M, Grunditz T, Ohlsson T, Ekblad E. Sodium/iodide-symporter: distribution in different mammals and role of entero-thyroid circulation of iodide. Acta Physiol Scand 2002;175:129–37. doi:10.1046/j.1365-201X.2002.00968.x.CrossRefPubMed

33.

Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 2004;34:23–31. doi:10.1053/j.semnuclmed.2003.09.004.CrossRefPubMed

34.

Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998;83:1746–51. doi:10.1210/jc.83.5.1746.CrossRefPubMed

35.

Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Pötter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002;29(7):842–54. doi:10.1007/s00259-002-0784-7.CrossRefPubMed

36.

Carlin S, Akabani G, Zalutsky MR. In vitro cytotoxicity of (211)At-astatide and (131)I-iodide to glioma tumour cells expressing the sodium/iodide symporter. J Nucl Med 2003;44(11):1827–38.PubMed

Title: Effective treatment of pancreatic neuroendocrine tumours transfected with the sodium iodide symporter gene by 186Re-perrhenate in mice
Authors: Christoph G. U. Riese
Stephan Seitz
Meike L. Schipper
Thomas M. Behr
Publication date: 01-11-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1153-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effective treatment of pancreatic neuroendocrine tumours transfected with the sodium iodide symporter gene by ¹⁸⁶Re-perrhenate in mice

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2009

EANM Springer Prizes 2009 Awarded

Scintigraphic visualization of bacterial translocation in experimental strangulated intestinal obstruction

Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation?

Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function

A different role for FDG PET/CT in axillary lymph node staging in breast cancer

Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma